Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06258291 | NOT YET RECRUITING | Septic Shock

First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression
Sponsor:

Hemotune AG

Brief Summary:

The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.

Condition or disease

Septic Shock

Intervention/treatment

Hemosystem REBOOT

Phase

NA

Detailed Description:

The treatment safety and the kinetics of specific biomarkers will be assessed to evaluate the selection of the treatment regimen. In a first step, 16 patients will be randomized 1:1 into two arms: Treatment arm 1: One treatment of 2 hours per day for a maximum of five days or until ICU discharge or death or withdrawal of consent, whichever occurs first. Control arm: Five consecutive days following the first mHLA-DR measurement post study randomization, or until ICU discharge or death or withdrawal of consent, whichever occurs first And the end of this treatment phase, it will be decided whether the dosage regimen of HemoSystem REBOOT needs to be adapted and another eight patients have to be enrolled with 2 treatments per day, and a maximum of five treatments.

Study Type : INTERVENTIONAL
Estimated Enrollment : 16 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)
Actual Study Start Date : 2025-09-01
Estimated Primary Completion Date : 2026-07-28
Estimated Study Completion Date : 2026-12-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Age ≥ 18 years
  • 2. Written informed consent according to national requirements.
  • 3. Hospitalized in ICU or IMC at randomization.
  • 4. Expected length of intensive care unit stay (from randomization) \>48 hours.
  • 5. Suspected or confirmed bacterial sepsis.
  • 6. Septic shock diagnosis at any time during ICU/IMC stay according to Sepsis - 3 criteria definition
    • 1. an infection (suspected or confirmed);
    • 2. persisting hypotension requiring any dose of vasopressors (norepinephrine, vasopressin) to maintain a systemic mean blood pressure \> 65 mmHg despite adequate fluid resuscitation (minimum of 30 ml/kg crystalloids);
    • 3. elevated lactate ≥ 2.0 mmol/L with suspected hypoperfusion.
    • 7. Persistent immunosuppression defined as mHLA-DR expression levels \< 5600 Ab/cell (Cyto-Chex tubes) in at least two consecutive measurements 20-72 hours apart.
    • Exclusion criteria
      • 1. Current ongoing chronic treatment using immunosuppressive biologicals or active lymphocyte therapy (e.g. endoxan, rituximab) or corticosteroid use at a dose \> 10 mg/day equivalent of prednisone. However, acute treatment using a maximum dose of hydrocortisone of 200 mg/day for sepsis is allowed.
      • 2. Patient with preexisting known severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS).
      • 3. Active or planned extracorporeal membrane oxygenation treatment.
      • 4. Active or planned other extracorporeal blood purification treatments with systems like CytoSorb®, ToraymyxinTM, Gambro Adsorba, etc.
      • 5. Patients post solid-organ transplantation.
      • 6. Known active malignancy (i.e. patients under active anti-malignant treatment).
      • 7. Acute severe burn injury \> 20% of the body surface area.
      • 8. Contraindication to use the HemoSystem
        • 1. Sensitivity / allergy to HemoSystem components
        • 2. Body weight \< 50 kg
        • 3. Platelets count \< 20,000/µL
        • 4. History of heparin-induced thrombocytopenia.
        • 9. Females who are known to be pregnant or known to be breastfeeding (b-HCG testing performed in female patients aged \< 55 years),
        • 10. Moribund patient with life expectancy \< 48h
        • 11. Known history of bleeding disorders or severe coagulopathies (e.g., Hemophilia A, Hemophilia B, Idiopathic Thrombocytopenic Purpura, Von Willebrand Disease types I, II, and III)
First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression

Location Details

NCT06258291

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

Switzerland,

University Hospital Bern Inselspital

Bern, Switzerland,

Not yet recruiting

Switzerland,

University Hospital Zurich

Zurich, Switzerland,